

Case 25


67 year old female. Left breast tumour. Mastectomy performed.


Case contributed by Dr Chih-Jung Chen, Taiwan




































A left breast tumor measuring 5.8x5.6x4.8 cm in size


An infiltrative tumor with marked necrosis


Simple mastectomy was done and sentinel LN (-)


Needle biopsy: malignant spindle cell tumor with CK(+) and p63(-)







































Mastectomy Courtesy of Dr Chih-Jung Chen



The FibroPhyllo™ Score Assay uses quantitative real time-PCR to determine the expression of a panel of 5 genes in breast fibroepithelial tissues. FibroPhyllo™ score is calculated from the gene expression results and scaled to between 0.0 to 1.0.

¹ Median value of 0.5 has been derived from the distribution of FibroPhyllo™ scores for 230 core biopsies in a clinical validation study¹. Breast fibroepithelial tissue subtyping has been reported based on this median value, such that samples with scores equal to or greater than 0.5 are predicted to be phyllodes tumor and samples with scores lower than 0.5 are predicted to be fibroadenomas. Scores are calculated on a continuous scale and are scaled to a value between 0.0 and 1.0. Pre-operative distinction between the two tissue subtypes have been reported to have significant impact on subsequent treatment management.¹

Lucence Diagnostics Pte Ltd

(T) +65 6909 0390 support@lucencedx.com

217 Henderson Road #03-08, Henderson Industrial Park, Singapore 159555

Lucence Diagnostics Pte Ltd is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory (License Number: 1710039/01/172)

Page 1 of 3




Diagnosis

Malignant spindle cell tumour, favour malignant phyllodes tumour









Phyllodes tumours & keratín expression

- In 1989, Auger et al described keratin expression in a malignant phyllodes tumour, where malignant stromal cells were positive for keratin on immunohistochemistry.
- On electron microscopy, stromal cells of one malignant phyllodes tumour displayed myoepithelial differentiation.

Arch Pathol Lab Med. 1989 Nov;113(11):1231-5.







Stromal keratin expression in phyllodes tumours of the breast: a comparison with other spindle cell breast lesions

Yifoong Chia, Aye Aye Thike, Poh Yian Cheok, Luke Yong-Zheng Chong, Gary Man-Kit Tse, Puay Hoon Tan

Table 6 Pattern of distribution of keratin immunohistochemical expression in phyllodes tumours

Cytokeratin	Periphery	Within the fronds	Subepithelial	Total
MNF 116	4 (30.8%)	4 (30.8%)	5 (38.5%)	13
34βΕ12	9 (37.5%)	8 (33.3%)	7 (29.2%)	24
CK7	10 (32.3%)	11 (35.5%)	10 (32.3%)	31
CK14	_	1 (50%)	1 (50%)	2
AE 1/3	3 (33.3%)	4 (44.4%)	2 (22.3%)	9
Cam 5.2	1 (50%)	_	1 (50%)	2



Conclusion The use of keratins as an adjunctive immunohistochemical diagnostic tool in the differential work-up of spindle cell tumours of the breast has to be interpreted with caution especially on limited core biopsy material.

J Clin Pathol 2012;65:339—347. (







Using adjunctive molecular tests ~ cautionary note

- Need to know what information is given by molecular test results.
- Fibrophyllo Tissue test assists in distinguishing fibroadenoma from phyllodes tumour.
- While the test in this case shows a result skewed towards a phyllodes tumour, it has not been validated in terms of distinction between metaplastic carcinoma and malignant phyllodes tumour.











CORRESPONDENCE

A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma

Joe Yeong^{1,2}
Aye Aye Thike¹
Cedric Chuan Young Ng³
Nur Diyana Md Nasir¹
Kiley Loh³
Bin Tean Teh³
Puay Hoon Tan¹

¹Division of Pathology, Singapore General Hospital, ²Singapore Immunology Network (SIgN), Agency of Science, Technology and Research (A*STAR), and ³National Cancer Center Singapore, Singapore









